drugset / Trial / NCT06052566
A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study was to evaluate the pharmacokinetics of efinopegdutide in participants with hepatic impairment compared to healthy participants, and to examine the safety and tolerability of efinopegdutide.
Timeline
- Start
- 2023-11-21
- Primary completion
- 2024-12-05
- Completion
- 2024-12-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efinopegdutide | Protein / enzyme biologic | 7 mg | Subcutaneous |